Seeking Alpha
10 Jun 2026, 21:32 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 2 movers · tap to explore
What the story claims
1 claim · each scored for market impact
Cullinan Therapeutics reported promising clinical data for CLN-978 and Velinotamig in the treatment of autoimmune diseases. — Positive clinical data for a pipeline candidate typically increases the probability of regulatory approval and future revenue growth.
+0.60Which stocks this story touches
The company is reporting promising clinical data for two of its drug candidates in autoimmune diseases.
Continue reading
6 related stories
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Seeking Alpha
4h ago
